Company news

Lantern Pharma Inc. news in 2022

Lantern Pharma Inc.'s news releases, calls and decks from 2022, newest first.

View company

Lantern Pharma Announces Positive New Data for its Drug Candidate LP-284 for Mantle Cell Lymphoma (MCL) at the American Society of Hematology (ASH) 2022 Annual Meeting

December 14, 2022

Lantern Pharma Announces Development of Drug Candidate LP-184 for Triple Negative Breast Cancer (TNBC) at the San Antonio Breast Cancer Symposium (SABCS)

December 12, 2022

Lantern Pharma Announces Positive Data Highlighting the Anti-Tumor Potency of Drug Candidate LP-184 for Glioblastoma at the Society for Neuro-Oncology Annual Meeting

November 21, 2022

Lantern Pharma Reports Third Quarter 2022 Financial Results and Operational Highlights

November 6, 2022

Lantern Pharma to Report Third Quarter 2022 Operating & Financial Results on November 7, 2022 at 4: 30 p.m. ET

October 30, 2022

Lantern Pharma Announces Issuance of New Patent that Strengthens Patent Portfolio for Cancer Drug Candidate LP-300

October 19, 2022

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-284 for Mantle Cell Lymphoma at the Society of Hematologic Oncology Annual Meeting

September 22, 2022

Lantern Pharma to Present Positive Preclinical Data on the Efficacy of LP-184 for Pancreatic Cancer at the AACR Special Conference for Pancreatic Cancer

September 13, 2022

Lantern Pharma Reports Second Quarter 2022 Financial Results and Operational Highlights

August 7, 2022

Lantern Pharma to Report Second Quarter 2022 Operating & Financial Results on August 8th, 2022 at 4: 30 p.m. ET

July 31, 2022

Lantern Pharma Receives FDA Authorization to Initiate its Phase 2 Clinical Trial, Harmonic™, for LP-300 in Never Smokers with Non-Small Cell Lung Cancer

July 13, 2022

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

May 2, 2022

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

April 25, 2022

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4: 30 p.m. ET

April 21, 2022

Lantern Pharma Announces Extension of Existing Share Repurchase Program

March 21, 2022

Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

March 13, 2022

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

March 9, 2022

Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

March 2, 2022

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

February 14, 2022

Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

January 23, 2022

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

January 17, 2022

Lantern Pharma Expands Precision Oncology Collaboration with the National Cancer Institute - Accelerating Path to First in Human Clinical Trials for Drug Candidates LP-184 & LP-284

January 11, 2022

Calls in 2022

Decks in 2022